Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects

Ruth O Payne, Paul M Griffin, James S McCarthy, Simon J Draper, Ruth O Payne, Paul M Griffin, James S McCarthy, Simon J Draper

Abstract

Modern controlled human malaria infection (CHMI) clinical trials have almost entirely focussed on Plasmodium falciparum, providing a highly informative means to investigate host-pathogen interactions as well as assess potential new prophylactic and therapeutic interventions. However, in recent years, there has been renewed interest in Plasmodium vivax, with CHMI models developed by groups in Colombia, the USA, and Australia. This review summarizes the published experiences, and examines the advantages and disadvantages of the different models that initiate infection either by mosquito bite or using a blood-stage inoculum. As for P. falciparum, CHMI studies with P. vivax will provide a platform for early proof-of-concept testing of drugs and vaccines, accelerating the development of novel interventions.

Keywords: CHMI; IBSM; malaria; vivax.

Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

References

    1. McCarthy J.S. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One. 2011;6:e21914.
    1. Pasay C.J. Piperaquine monotherapy of drug-susceptible Plasmodium falciparum infection results in rapid clearance of parasitemia but is followed by the appearance of gametocytemia. J. Infect. Dis. 2016;214:105–113.
    1. Sauerwein R.W. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat. Rev. Immunol. 2011;11:57–64.
    1. Sheehy S.H. optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLoS One. 2013;8:e65960.
    1. Engwerda C.R. Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol. 2012;28:515–521.
    1. Duncan C.J., Draper S.J. Controlled human blood stage malaria infection: current status and potential applications. Am. J. Trop. Med. Hyg. 2012;86:561–565.
    1. Duncan C.J. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel + CPG 7909. PLoS One. 2011;6:e22271.
    1. Cheng Q. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am. J. Trop. Med. Hyg. 1997;57:495–500.
    1. Roestenberg M. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 2013;88:5–13.
    1. Mordmuller B. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malaria J. 2015;14:117.
    1. Stanisic D.I. Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. Malaria J. 2015;14:143.
    1. Teirlinck A.C. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J. Infect. Dis. 2013;207:656–660.
    1. Spring M. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine. 2013;31:4975–4983.
    1. Hodgson S.H. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front. Microbiol. 2014;5:686.
    1. Shekalaghe S. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 2014;91:471–480.
    1. Whitrow M. Wagner-Jauregg and fever therapy. Med. History. 1990;34:294–310.
    1. Snounou G., Perignon J.L. Malariotherapy – insanity at the service of malariology. Adv. Parasitol. 2013;81:223–255.
    1. Alving A.S. Procedures used at Stateville penitentiary for the testing of potential antimalarial agents. J. Clin. Invest. 1948;27:2–5.
    1. Coatney H.R. Studies in human malaria; trials of quinacrine, colchicine (SN 12,080) and quinine against Chesson strain vivax malaria. Am. J. Hyg. 1949;50:194–199.
    1. Miller L.H. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N. Engl. J. Med. 1976;295:302–304.
    1. Rieckmann K.H. Current considerations in vaccination of humans against malaria: Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull. Wld. Hlth. Organ. 1979;57(Suppl.):261–265.
    1. Clyde D.F. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am. J. Trop. Med. Hyg. 1975;24:397–401.
    1. Clyde D.F. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 1973;266:398–403.
    1. McCarthy V.C., Clyde D.F. Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. Exp. Parasitol. 1977;41:167–171.
    1. Hoffman S.L. The march toward malaria vaccines. Am. J. Prev. Med. 2015;49(6 Suppl. 4):S319–S333.
    1. Herrera S. Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors. Am. J. Trop. Med. Hyg. 2009;81:740–746.
    1. Herrera S. Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am. J. Trop. Med. Hyg. 2011;84(2 Suppl.):4–11.
    1. Arevalo-Herrera M. Plasmodium vivax sporozoite challenge in malaria-naive and semi-immune Colombian volunteers. PLoS One. 2014;9:e99754.
    1. Rojas-Pena M.L. Transcription profiling of malaria-naive and semi-immune Colombian volunteers in a Plasmodium vivax sporozoite challenge. PLoS Negl. Trop. Dis. 2015;9:e0003978.
    1. Arevalo-Herrera M. Antibody Profiling in Naive and Semi-immune Individuals Experimentally Challenged with Plasmodium vivax Sporozoites. PLoS Negl. Trop. Dis. 2016;10:e0004563.
    1. Arevalo-Herrera M. Protective efficacy of Plasmodium vivax radiation-attenuated sporozoites in Colombian volunteers: a randomized controlled trial. PLoS Negl. Trop. Dis. 2016;10:e0005070.
    1. Bennett J.W. Phase 1/2a Trial of Plasmodium vivax malaria vaccine candidate VMP001/AS01B in malaria-naive adults: safety, immunogenicity, and efficacy. PLoS Negl. Trop. Dis. 2016;10:e0004423.
    1. Vanloubbeeck Y. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques. Vaccine. 2013;31:6216–6224.
    1. Bennett J.W. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N. Engl. J. Med. 2013;369:1381–1382.
    1. McCarthy J.S. Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J. Infect. Dis. 2013;208:1688–1694.
    1. Payne R.O. Demonstration of the blood-stage Plasmodium falciparum controlled human malaria infection model to assess efficacy of the P. falciparum apical membrane antigen 1 vaccine, FMP2.1/AS01. J. Infect. Dis. 2016;213:1743–1751.
    1. Griffin P. Safety and reproducibility of a clinical trial system using induced blood stage Plasmodium vivax infection and its potential as a model to evaluate malaria transmission. PLoS Negl. Trop. Dis. 2016;10:e0005139.
    1. Vallejo A.F. Plasmodium vivax gametocyte infectivity in sub-microscopic infections. Malaria J. 2016;15:48.
    1. Pukrittayakamee S. Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria. Am. J. Trop. Med. Hyg. 2008;79:378–384.
    1. Kerlin D.H., Gatton M.L. A simulation model of the within-host dynamics of Plasmodium vivax infection. Malaria J. 2015;14:51.
    1. Roestenberg M. Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers. J. Infect. Dis. 2012;206:319–323.
    1. Spring M. Controlled human malaria infection. J. Infect. Dis. 2014;209(Suppl. 2):S40–S45.
    1. Chulay J.D. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am. J. Trop. Med. Hyg. 1986;35:66–68.
    1. Ballou W.R. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1987;1:1277–1281.
    1. Herrington D.A. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature. 1987;328:257–259.
    1. Church L.W. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J. Infect. Dis. 1997;175:915–920.
    1. Berman J.D. Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. Trans. R. Soc. Trop. Med. Hyg. 2001;95:429–432.
    1. Shapiro T.A. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am. J. Trop. Med. Hyg. 1999;60:831–836.
    1. Somsak V. Transgenic Plasmodium parasites stably expressing Plasmodium vivax dihydrofolate reductase-thymidylate synthase as in vitro and in vivo models for antifolate screening. Malaria J. 2011;10:291.
    1. Mizutani M. Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites. Infect. Immun. 2014;82:4348–4357.
    1. de Cassan S.C. Preclinical assessment of viral vectored and protein vaccines targeting the Duffy-binding protein region II of Plasmodium Vivax. Front. Immunol. 2015;6:348.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe